BioMarin Acquires Inozyme Pharma to Expand Enzyme Therapy Portfolio Amid Market Volatility
BioMarin Pharmaceutical Inc. has acquired Inozyme Pharma, expanding its enzyme therapy portfolio and positioning itself as a frontrunner in addressing rare diseases.
3 minutes to read